var data={"title":"Nitroglycerin (glyceryl trinitrate): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitroglycerin (glyceryl trinitrate): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6662?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitroglycerin (glyceryl trinitrate): Patient drug information&quot;</a> and <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nitroglycerin (glyceryl trinitrate): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202098\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>GoNitro;</li>\n      <li>Minitran;</li>\n      <li>Nitro-Bid;</li>\n      <li>Nitro-Dur;</li>\n      <li>Nitro-Time;</li>\n      <li>Nitrolingual;</li>\n      <li>NitroMist;</li>\n      <li>Nitronal [DSC];</li>\n      <li>Nitrostat;</li>\n      <li>Rectiv</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202099\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Minitran;</li>\n      <li>Mylan-Nitro Sublingual Spray;</li>\n      <li>Nitro-Dur;</li>\n      <li>Nitroglycerin Injection, USP;</li>\n      <li>Nitrol;</li>\n      <li>Nitrostat;</li>\n      <li>Rho-Nitro Pump Spray;</li>\n      <li>Transderm-Nitro;</li>\n      <li>Trinipatch</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202148\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antianginal Agent;</li>\n      <li>\n        Antidote, Extravasation;</li>\n      <li>\n        Vasodilator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202103\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Nitronal IV solution has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Hemodynamic and antianginal tolerance often develop within 24 to 48 hours of continuous nitrate administration. Nitrate-free interval (10 to 12 hours/day) is recommended to avoid tolerance development; gradually decrease dose in patients receiving nitroglycerin for prolonged period to avoid withdrawal reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute decompensated heart failure (off-label dose): </b> IV: Initial: 10 to 20 mcg/minute, with subsequent titration (eg, 10 to 20 mcg/minute every 5 to 15 minutes) up to 200 mcg/minute (Coons 2011; Mebazaa 2016) <b>or </b>0.3 to 0.5 mcg/<b>kg</b>/minute with titration (if SBP &ge;90 mm Hg) in increments of 20 mcg/minute every 1 to 3 minutes up to 400 mcg/minute (Levy 2007). Patients who do not respond hemodynamically with doses of ~200 mcg/minute should be considered non-responders (Coons 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Angina/coronary artery disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial: 2.5 to 6.5 mg 3 to 4 times daily; may titrate up to 26 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 5 mcg/minute, increase by 5 mcg/minute every 3 to 5 minutes to 20 mcg/minute. If no response at 20 mcg/minute, may increase by 10 to 20 mcg/minute every 3 to 5 minutes (generally accepted maximum dose: 400 mcg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: ACCF/AHA guidelines for STEMI: Initial: 10 mcg/minute, with subsequent titration to desired blood pressure effect (ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sublingual powder (0.4 mg/packet):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 1 to 2 packets under tongue every 5 minutes as needed for maximum of 3 packets in 15 minutes; may also use prophylactically 5 to 10 minutes prior to activities which may provoke an angina attack</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: ACCF/AHA guidelines for STEMI and AHA/ACC guidelines for the management of NSTE-ACS: 0.4 mg every 5 minutes up to 3 doses. Patients should be advised to take 1 dose promptly in response to chest pain. If pain is unrelieved or worsened 3 to 5 minutes after 1 dose, the patient or caregiver should call 9-1-1 immediately (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sublingual tablet:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 0.3 to 0.6 mg every 5 minutes for maximum of 3 tablets in 15 minutes; may also use prophylactically 5 to 10 minutes prior to activities which may provoke an attack.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: ACCF/AHA guidelines for STEMI and AHA/ACC guidelines for the management of NSTE-ACS: 0.3 to 0.4 mg every 5 minutes up to 3 doses. Patients should be advised to take 1 dose promptly in response to chest pain. If pain is unrelieved or worsened 3 to 5 minutes after 1 dose, the patient or caregiver should call 9-1-1 immediately (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Topical 2% ointment: </i> <sup>1</sup>/<sub>2</sub>&rdquo; upon rising and <sup>1</sup>/<sub>2</sub>&rdquo; 6 hours later; if necessary, the dose may be doubled to 1&rdquo; and subsequently doubled again to 2&rdquo; if response is inadequate. Doses of <sup>1</sup>/<sub>2</sub>&rdquo; to 2&rdquo; were used in clinical trials. Recommended maximum: 2 doses/day; include a nitrate free-interval ~10 to 12 hours/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Topical patch, transdermal:</i> 0.2 to 0.4 mg/hour initially and titrate to doses of 0.4 to 0.8 mg/hour. Tolerance is minimized by using a patch-on period of 12 to 14 hours/day and patch-off period of 10 to 12 hours/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Translingual 0.4 mg/spray:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 1 to 2 sprays onto or under tongue approximately every 5 minutes for maximum of 3 sprays in 15 minutes, may also be used prophylactically 5 to 10 minutes prior to activities which may provoke an angina attack</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: ACCF/AHA guidelines for STEMI and AHA/ACC guidelines for the management of NSTE-ACS: 0.4 mg every 5 minutes up to 3 doses. Patients should be advised to take 1 dose promptly in response to chest pain. If pain is unrelieved or worsened 3 to 5 minutes after 1 dose, the patient or caregiver should call 9-1-1 immediately (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anal fissure, chronic (0.4% ointment):</b> Intra-anal: 1 inch (equals 1.5 mg of nitroglycerin) every 12 hours for up to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal spastic disorders (off-label use): </b> Sublingual: 0.3 to 0.6 mg (Swamy 1977). Additional data may be necessary to further define the role of nitroglycerin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal variceal hemorrhage (off-label use):</b> IV infusion: Initial: 40 mcg/minute, increase by 40 mcg/minute every 15 minutes if systolic blood pressure is &gt;90 to 100 mm Hg, up to a maximum of 400 mcg/minute (Garcia-Tsao 2007; Gimson 1986; Westaby 1989). Coadminister with vasopressin and use at the highest effective dose for a maximum of 24 hours to minimize the development of adverse effects (Garcia-Tsao 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sympathomimetic vasopressor extravasation injury (alternative to phentolamine) (off-label use; based on limited data): </b>Topical 2% ointment: Apply a 1-inch strip to site of ischemia; may repeat every 8 hours if needed (Reynolds 2014). Additional data may be necessary to further define the role of topical nitroglycerin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uterine relaxation (off-label use):</b> IV bolus: 100 to 200 mcg; may repeat dose every 2 minutes as necessary (Axemo 1998; Chandraharan 2005). Additional data may be necessary to further define the role of nitroglycerin in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20614012\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nitroglycerin (glyceryl trinitrate): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Nitronal IV solution has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sympathomimetic vasopressor extravasation injury (alternative to phentolamine) (off-label use; based on limited data): </b>Topical 2% ointment: 4 mm/kg applied as a thin ribbon to site of ischemia; may repeat after 8 hours if needed (Wong 1992) <b>or</b> apply a 1-inch strip to site of ischemia; may repeat every 8 hours if needed (Denkler 1989; Reynolds 2014). Additional data may be necessary to further define the role of topical nitroglycerine in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202104\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210506\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210507\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202076\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Translingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NitroMist: 400 mcg/spray (4.1 g, 8.5 g) [contains menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mcg/spray (4.1 g [DSC], 8.5 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Time: 2.5 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Time: 6.5 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Time: 9 mg [contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 6.5 mg, 9 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectiv: 0.4% (30 g) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Bid: 2% (1 g, 30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoNitro: 400 mcg (1 ea, 36 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch 24 Hour, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minitran: 0.1 mg/hr (30 ea); 0.2 mg/hr (30 ea); 0.4 mg/hr (30 ea); 0.6 mg/hr (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Dur: 0.1 mg/hr (30 ea, 100 ea); 0.2 mg/hr (30 ea, 100 ea); 0.3 mg/hr (1 ea, 30 ea, 100 ea); 0.4 mg/hr (30 ea, 100 ea); 0.6 mg/hr (30 ea, 100 ea); 0.8 mg/hr (30 ea, 100 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg/hr (1 ea, 30 ea, 4350 ea); 0.2 mg/hr (1 ea, 30 ea, 4350 ea); 0.4 mg/hr (1 ea, 30 ea, 4350 ea); 0.6 mg/hr (1 ea, 30 ea, 4350 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitronal: 1 mg/mL (25 mL [DSC], 50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg (250 mL); 50 mg (250 mL, 500 mL [DSC]); 100 mg (250 mL); 200 mg (500 mL [DSC]); 5 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Translingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitrolingual: 0.4 mg/spray (4.9 g, 12 g) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/spray (4.9 g, 12 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitrostat: 0.3 mg, 0.4 mg, 0.6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.3 mg, 0.4 mg, 0.6 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202061\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50063776\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Nitronal IV solution has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F803176\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Prepare in glass bottles, EXCEL or PAB containers. Adsorption occurs to soft plastic (eg, PVC); use administration sets intended for nitroglycerin. Avoid in-line IV filters that adsorb nitroglycerin. Administer via infusion pump.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intra-anal ointment: Using a finger covering (eg, plastic wrap, surgical glove, finger cot), place finger beside 1 inch measuring guide on the box and squeeze ointment the length of the measuring line directly onto covered finger. Insert ointment into the anal canal using the covered finger up to first finger joint (do not insert further than the first finger joint) and apply ointment around the side of the anal canal. If intra-anal application is too painful, may apply the ointment to the outside of the anus. Wash hands following application.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release capsule: Swallow whole. Do not chew, break, or crush. Administer with a full glass of water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual powder: Empty the contents of packet under the tongue, close mouth, and breathe normally. Allow powder to dissolve without swallowing. Do not rinse or spit for 5 minutes after dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet: Do not chew, crush, or swallow sublingual tablet. Place under tongue and allow to dissolve. Alternately, may be placed in the buccal pouch. May take small sip of water prior to placing tablet under the tongue to aid dissolution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical ointment: Wash hands prior to and after use. Application site should be clean, dry, and hair-free. Apply to chest or back with the applicator or dose-measuring paper. Spread in a thin layer over a 2.25 x 3.5 inch area. Do not rub into skin. Tape applicator into place.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sympathomimetic vasopressors extravasation injury (alternative to phentolamine) (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula; elevate extremity. Apply nitroglycerin ointment as a thin ribbon to site of ischemia (Reynolds 2014; Wong 1992). May also apply dry warm compresses (Hurst 2004; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical patch, transdermal: Application site should be clean, dry and hair-free. Remove patch after 12 to 14 hours. Rotate patch sites. Dispose of any used of unused patches by folding adhesive ends together, replace in pouch or sealed container and discard properly in trash, away from children and pets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Translingual spray: Do not shake container. Prior to initial use, the pump must be primed by spraying 5 times (Nitrolingual) or 10 times (Nitromist) into the air. Priming sprays should be directed away from patient and others. Release spray onto or under tongue. Close mouth immediately after administration; do not inhale spray. Do not expectorate or rinse the mouth for 5 to 10 minutes following administration. Content of the container should be checked periodically; when the container is held upright, the end of the pump should be covered by the fluid in the bottle or the remaining sprays will not deliver the intended dose. If pump is unused for 6 weeks, a single priming spray (Nitrolingual) or 2 priming sprays (Nitromist) should be completed. If pump is unused for 3 months, re-prime with up to 5 sprays (Nitrolingual).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472967\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 50 mg in 250 mL (concentration: 200 <b>mcg</b>/mL) <b>or</b> 100 mg in 250 mL (concentration: 400 <b>mcg</b>/mL) of D5W</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472968\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 100 <b>mcg</b>/mL, 200 <b>mcg</b>/mL, or 400 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202079\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment or prevention of angina pectoris</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Intravenous (IV) administration: Treatment or prevention of angina pectoris; acute decompensated  heart failure (especially when associated with acute myocardial infarction); perioperative hypertension (especially during cardiovascular surgery); induction of intraoperative hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Intra-anal administration (Rectiv ointment): Treatment of moderate-to-severe pain associated with chronic anal fissure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469146\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Esophageal spastic disorders; Gastroesophageal variceal hemorrhage; Sympathomimetic vasopressor extravasation injury (alternative to phentolamine); Uterine relaxation; Short-term management of pulmonary hypertension (IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202157\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitroglycerin may be confused with nitrofurantoin, nitroprusside</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitro-Bid may be confused with Macrobid</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitroderm may be confused with NicoDerm</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitrol may be confused with Nizoral</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitrostat may be confused with Nilstat, nystatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Vasodilators are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older with a history of syncope due to its potential to exacerbate episodes of syncope (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitrocor [Italy, Russia, and Venezuela] may be confused with Natrecor brand name for nesiritide [US, Canada, and multiple international markets]; Nutracort brand name for hydrocortisone in the [US and multiple international markets]; Nitro-Dur [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4040394\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Headache (patch, ointment: 50% to 64%; sublingual powder, lingual spray: &gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (&le;4%), syncope (&le;4%), peripheral edema (lingual spray: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&gt;2% to 6%), paresthesia (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (lingual spray: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (all sublingual forms: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (&le;2%), pharyngitis (lingual spray: &le;2%), rhinitis (lingual spray: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia, exacerbation of angina pectoris, flushing, orthostatic hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Drug tolerance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, application site irritation (patch), circulatory shock, contact dermatitis (ointment, patch), drowsiness, exfoliative dermatitis, fixed drug eruption (ointment, patch), hypersensitivity reaction, hypoxemia (transient), methemoglobinemia, nausea, pallor, palpitations, rebound hypertension, restlessness, skin rash, tachycardia, vertigo, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202082\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to nitroglycerin, other nitrates or nitrites, or any component of the formulation (includes adhesives for transdermal product); concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (avanafil, sildenafil, tadalafil, or vardenafil); concurrent use with soluble guanylate cyclase (sGC) stimulators (eg, riociguat).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for IV product: Hypersensitivity to corn or corn products (solutions containing dextrose); constrictive pericarditis; increased intracranial pressure; pericardial tamponade; restrictive cardiomyopathy; uncorrected hypovolemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for sublingual product and rectal ointment: Acute circulatory failure or shock (sublingual tablets and powder); early myocardial infarction (sublingual tablet only; see <b>Note</b>); increased intracranial pressure; severe anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for translingual product: Increased intracranial pressure; severe anemia; acute circulatory failure or shock (Nitrolingual only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications for translingual product (not in US labeling): Closed angle glaucoma; myocardial infarction; heart failure (aortic or mitral stenosis, constrictive pericarditis or hypertrophic obstructive cardiomyopathy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications for transdermal patch (not in US labeling): Acute circulatory failure associated with marked hypotension (shock and states of collapse); orthostatic hypotension; myocardial insufficiency due to obstruction (eg, presence of aortic or mitral stenosis or of constrictive pericarditis); increased intracranial pressure; increased intraocular pressure; severe anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> According to the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines of the management of ST-elevation myocardial infarction (STEMI) and the ACC/AHA guidelines for the management of patients with non-ST-elevation acute coronary syndromes (NSTE-ACS), avoid nitrates in the following conditions: Hypotension (SBP &lt;90 mm Hg or &ge;30 mm Hg below baseline), marked bradycardia or tachycardia, and right ventricular infarction (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]). Sublingual nitroglycerin may be used as initial treatment of ongoing chest pain in patients who may have STEMI or NSTE-ACS (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202065\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Headache: Dose-related headaches may occur, especially during initial dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/bradycardia: Severe hypotension and shock may occur (even with small doses); paradoxical bradycardia and increased angina pectoris may accompany hypotension. Orthostatic hypotension may also occur; ethanol may accentuate this. Use with caution in volume depletion, preexisting hypotension, constrictive pericarditis, aortic or mitral stenosis, and extreme caution with inferior wall MI and suspected right ventricular involvement. According to the ACCF/AHA, avoid use in patients with severe hypotension (SBP &lt;90 mm Hg or &ge;30 mm Hg below baseline), marked bradycardia or tachycardia, and right ventricular MI (ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: Nitroglycerin may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury) (Rangel-Castilla 2008). Some products are contraindicated in patients with increased intracranial pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic cardiomyopathy (HCM): Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (ACCF/AHA [Gersh, 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intra-anal ointment: Use caution when treating rectal anal fissures with nitroglycerin in patients with suspected or known significant cardiovascular disorders (eg, cardiomyopathies, heart failure, acute MI); intra-anal nitroglycerin administration may decrease systolic blood pressure and decrease arterial vascular resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-acting agents: Avoid use of long-acting agents in acute MI or acute HF; cannot easily reverse effects if adverse events develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patches: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: May occur; cross tolerance to other nitro compounds have been reported. Appropriate dosing is needed to minimize tolerance development.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299768\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4039431\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9706&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Nitroglycerin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alteplase: Nitroglycerin may decrease the serum concentration of Alteplase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.<b> Exceptions: </b>Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: Nitroglycerin may diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilmenidine: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of ischemia and other adverse effects has been associated with this combination in some pooled analyses. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202072\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (product specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11313090\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with all products; adverse events were not observed in animal reproduction studies conducted using the ointment. Nitroglycerin crosses the placenta (David 2000). Concentrations following application of a transdermal patch 0.4 mg/hour were low but detectable in the fetal serum (fetal/maternal ratio: 0.23) (Bustard 2003). Nitroglycerin may be used in pregnancy when immediate relaxation of the uterus is needed (ACOG 183 2017; Axemo 1998; Chandraharan 2005). Intravenous nitroglycerin may be used to treat pre-eclampsia with pulmonary edema (ESG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617179\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if nitroglycerin is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Information related to the use of nitroglycerin and breastfeeding is limited (B&ouml;ttiger 2010; O&rsquo;Sullivan 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202074\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate; consult individual institutional policies and procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202064\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nitroglycerin forms free radical nitric oxide. In smooth muscle, nitric oxide activates guanylate cyclase which increases guanosine 3&rsquo;5&rsquo; monophosphate (cGMP) leading to dephosphorylation of myosin light chains and smooth muscle relaxation. Produces a vasodilator effect on the peripheral veins and arteries with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload; dilates coronary arteries and improves collateral flow to ischemic regions. For use in rectal fissures, intra-anal administration results in decreased sphincter tone and intra-anal pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202081\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Sublingual tablet: 1 to 3 minutes; Translingual spray: Similar to sublingual tablet; Extended release: ~60 minutes; Topical: 15 to 30 minutes; Transdermal: ~30 minutes; IV: Immediate </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Sublingual powder: 7 minutes; Sublingual tablet: 5 minutes; Translingual spray: 4 to 15 minutes; Extended release: 2.5 to 4 hours; Topical: ~60 minutes; Transdermal: 120 minutes; IV: Immediate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Sublingual tablet: At least 25 minutes; Translingual spray: Similar to sublingual tablet; Extended release: 4 to 8 hours (Gibbons 2002); Topical: 7 hours; Transdermal: 10 to 12 hours; IV: 3 to 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 60% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive first-pass effect; metabolized hepatically to glycerol di- and mononitrate metabolites via liver reductase enzyme; subsequent metabolism to glycerol and organic nitrate; nonhepatic metabolism via red blood cells and vascular walls also occurs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~1 to 4 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as inactive metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202085\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (NitroMist Translingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg/spray (4.1 g): $227.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Nitro-Time Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (60): $54.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.5 mg (60): $60.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (60): $70.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Nitroglycerin ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (60): $53.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.5 mg (60): $60.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (60): $66.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Nitro-Bid Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (30 g): $38.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Rectiv Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4% (30 g): $732.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (GoNitro Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (1): $8.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Minitran Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/hour (30): $597.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/hour (30): $616.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/hour (30): $680.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/hour (30): $737.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Nitro-Dur Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/hour (30): $165.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/hour (30): $178.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/hour (30): $200.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/hour (30): $200.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/hour (30): $217.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg/hour (30): $217.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Nitroglycerin Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/hour (30): $55.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/hour (30): $50.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/hour (30): $56.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/hour (30): $61.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitroglycerin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL 5% (250 mL): $21.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/mL 5% (250 mL): $23.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitroglycerin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (10 mL): $16.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitroglycerin Translingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/spray (4.9 g): $224.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitrolingual Translingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/spray (4.9 g): $330.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Nitroglycerin Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $47.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg (25): $25.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $47.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Nitrostat Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $68.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg (25): $37.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $68.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202086\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Angiderm Patch (KR);</li>\n      <li>Anginine (AU);</li>\n      <li>Angised (HR, KW, QA, SG);</li>\n      <li>Cardiplast (ES);</li>\n      <li>Cardispray (AE);</li>\n      <li>Cardnit (PK);</li>\n      <li>Deponit (CN, DE, HU, LU, MY, PE, PH);</li>\n      <li>Deponit NT (IL);</li>\n      <li>Dermatrans (ES);</li>\n      <li>Diafusor (LU);</li>\n      <li>Domitral (VN);</li>\n      <li>Enetege (UY);</li>\n      <li>Epinitril (FR);</li>\n      <li>Glytrin (IE, TR);</li>\n      <li>Glytrin Spray (NZ, SG);</li>\n      <li>Herzer (JP);</li>\n      <li>Lycinate (AU);</li>\n      <li>Millisrol (JP);</li>\n      <li>Minitran (AU, BE, CR, DO, GR, GT, HN, LU, MT, PA, SV, UY);</li>\n      <li>Myovin (IN);</li>\n      <li>Natispray (LU);</li>\n      <li>Niglinar (PE);</li>\n      <li>Nit-Ret (CZ);</li>\n      <li>Nitracor (PL);</li>\n      <li>Nitradisc (LU, MX, PT);</li>\n      <li>Nitradisc TTS (GR);</li>\n      <li>Nitral (ID);</li>\n      <li>Nitriderm TTS (FR);</li>\n      <li>Nitril (LK);</li>\n      <li>Nitro (FI, HU);</li>\n      <li>Nitro Mack (LU);</li>\n      <li>Nitro Mack Retard (AE, AT, BH, CY, CZ, EG, GR, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nitro Pohl (HU);</li>\n      <li>Nitro-Dur (AE, AU, BB, CH, ES, HU, IT, NO, PL, PT, QA, SA);</li>\n      <li>Nitro-Dur 10 (IL);</li>\n      <li>Nitro-Mack (PL);</li>\n      <li>Nitro-Pflaster (DE);</li>\n      <li>Nitro-Pflaster-ratiopharm (LU);</li>\n      <li>Nitrobaat (BE, NL);</li>\n      <li>Nitrocard (PL);</li>\n      <li>Nitrocerin (GR);</li>\n      <li>Nitrocine (CN, EE, ID, IE);</li>\n      <li>Nitrocine 5 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nitrocontin (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LK, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Nitrocontin Continus (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nitrocor (IT);</li>\n      <li>Nitroderm (VE);</li>\n      <li>Nitroderm TTS (AE, AR, AT, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CY, DE, EC, EG, ES, ET, GH, GM, GN, GY, HR, HU, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NZ, OM, PL, PT, QA, RO, SA, SC, SD, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Nitroderm TTS Ext (CZ);</li>\n      <li>Nitroderm TTS-5 (NI);</li>\n      <li>Nitrodisc (BM, BS, BZ, GY, JM, MY, SR, TT);</li>\n      <li>Nitrodom (AR);</li>\n      <li>Nitrodyl (GR, LU);</li>\n      <li>Nitrodyl TTS (GR);</li>\n      <li>Nitrogesic (UY);</li>\n      <li>Nitroglycerinum (PL);</li>\n      <li>Nitroglycerinum prolongatum (PL);</li>\n      <li>Nitrol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nitrolingual (AE, AT, BE, CH, DE, DK, GB, GR, HK, HU, IE, KR, LT, LU, MT, NL, PH, PT, SE, SI, TW);</li>\n      <li>Nitrolingual Pumpspray (AU);</li>\n      <li>Nitrolingual Spray (KR, NZ, PH);</li>\n      <li>Nitromack Retard (PY);</li>\n      <li>Nitromaks (UA);</li>\n      <li>Nitromex (NO, SE);</li>\n      <li>Nitromint (HU, PL, RO, SK, TH, UA, VN);</li>\n      <li>Nitromint Aerosol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Nitromint Khi dung (VN);</li>\n      <li>Nitromint Retard (AE, BH, BM, BS, BZ, CY, EG, GY, IQ, IR, JM, JO, KW, LB, LY, OM, QA, SA, SR, SY, TT, YE);</li>\n      <li>Nitronal (FR, RO);</li>\n      <li>Nitronal Aqueous (PH);</li>\n      <li>Nitronal Spray (FR);</li>\n      <li>Nitrong (BE, LU, MT, TR);</li>\n      <li>Nitrong Retard (AT, GR);</li>\n      <li>Nitroplast (ES);</li>\n      <li>Nitroplus (LK);</li>\n      <li>Nitrosol Spray (MY);</li>\n      <li>Nitrospray (UA);</li>\n      <li>Nitrostad Retard (VN);</li>\n      <li>Nitrostat (TW);</li>\n      <li>Nitrovas (BD);</li>\n      <li>Nitrozell Retard (AT, NL);</li>\n      <li>NTG (ID);</li>\n      <li>Nysconitrine (LU);</li>\n      <li>Nyserin (PH);</li>\n      <li>Perlinganit (BG, HU, KR, LU, PL);</li>\n      <li>Ratiopharm (DE);</li>\n      <li>Rectogesic (AU, BE, CH, CZ, DE, DK, FI, FR, GB, IE, IL, IT, NL, NO, NZ, PT, SE, SG, SK, TR);</li>\n      <li>Rectogesic Ointment (KR);</li>\n      <li>Sustac (AE, BH, BM, BS, BZ, CY, EG, GY, HR, HU, IQ, IR, JM, JO, KW, LB, LY, OM, QA, SA, SR, SY, TT, YE);</li>\n      <li>Sustonit (PL);</li>\n      <li>Transiderm Nitro (AU, FI, IE, NL, NO, SE);</li>\n      <li>Tridil (BR);</li>\n      <li>Trimonit (PL);</li>\n      <li>Trinipatch (LU);</li>\n      <li>Venitrin (IT);</li>\n      <li>Willlong (LU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Committee on Practice Bulletins-Obstetrics. Practice bulletin no. 183: postpartum hemorrhage. <i>Obstet Gynecol</i>. 2017;130(4):e168-e186. doi: 10.1097/AOG.0000000000002351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/28937571/pubmed\" target=\"_blank\" id=\"28937571\">28937571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9492718\"></a>Axemo P, Fu X, Lindberg B, et al, &quot;Intravenous Nitroglycerin for Rapid Uterine Relaxation,&quot; <i>Acta Obstet Gynecol Scand</i>, 1998, 77(1):50-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/9492718/pubmed\" target=\"_blank\" id=\"9492718\">9492718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    B&ouml;ttiger Y, &quot;Lack of Data on Glyceryl Trinitrate Risks in Breast Feeding,&quot; <i>Lakartidningen</i>, 2010, 107(22):1483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/20645601/pubmed\" target=\"_blank\" id=\"20645601\">20645601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo; <i>J Am Coll Cardiol</i>, 2002, 40(7):1366-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/12383588/pubmed\" target=\"_blank\" id=\"12383588\">12383588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bustard MA, Ryan G, Seaward G, et al, &quot;Human Maternal and Fetal Plasma Glyceryl Trinitrate Concentrations,&quot; <i>Am J Obstet Gynecol</i>, 2003, 189(6):1777-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/14710114/pubmed\" target=\"_blank\" id=\"14710114\">14710114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chandraharan E and Arulkumaran S, &quot;Acute Tocolysis,&quot; <i>Curr Opin Obstet Gynecol</i>, 2005, 17(2):151-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/15758607/pubmed\" target=\"_blank\" id=\"15758607\">15758607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;ACC/AHA Expert Consensus Document. Use of Sildenafil (Viagra&reg;) in Patients With Cardiovascular Disease. American College of Cardiology/American Heart Association,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(1):273-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/9935041/pubmed\" target=\"_blank\" id=\"9935041\">9935041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21164062\"></a>Coons JC, McGraw M, Murali S. Pharmacotherapy for acute heart failure syndromes. <i>Am J Health Syst Pharm</i>. 2011;68(1):21-35. doi:10.2146/ajhp100202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/21164062/pubmed\" target=\"_blank\" id=\"21164062\">21164062</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corwin S and Reiffel JA, &ldquo;Nitrate Therapy for Angina Pectoris. Current Concepts About Mechanism of Action and Evaluation of Currently Available Preparations,&rdquo; A<i>rch Intern Med</i>, 1985, 145(3):538-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/3919668/pubmed\" target=\"_blank\" id=\"3919668\">3919668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    David M, Walka MM, Schmid B, et al, &quot;Nitroglycerin Application During Cesarean Delivery: Plasma Levels, Fetal/Maternal Ratio of Nitroglycerin, and Effects in Newborns,&quot;<i> Am J Obstet Gynecol</i>, 2000, 182(4):955-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/10764480/pubmed\" target=\"_blank\" id=\"10764480\">10764480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2510208\"></a>Denkler KA and Cohen BE, &ldquo;Reversal of Dopamine Extravasation Injury With Topical Nitroglycerin Ointment,&rdquo; <i>Plast Reconstr Surg</i>, 1989, 84(5):811-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/2510208/pubmed\" target=\"_blank\" id=\"2510208\">2510208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(1):66-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/10669188/pubmed\" target=\"_blank\" id=\"10669188\">10669188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al, &quot;ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy: The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC),&quot; <i>Eur Heart J</i>, 2011, 32(24):3147-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis [published correction appears in <i>Hepatology</i>. 2007;46(6):2052]. <i>Hepatology</i>. 2007;46(3):922-938.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/17879356/pubmed\" target=\"_blank\" id=\"17879356\">17879356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(24):e783-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons, RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). 2002. Available at www.acc.org/clinical/guidelines/stable/stable.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gimson AE, Westaby D, Hegarty J, Watson A, Williams R. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. <i>Hepatology</i>. 1986;6(3):410-413.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/3086204/pubmed\" target=\"_blank\" id=\"3086204\">3086204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GoNitro (nitroglycerin) [prescribing information]. Jacksonville, FL: Espero Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goyal RK, &quot;Diseases of the Esophagus,&quot; <i>Harrison&rsquo;s Principles of Internal Medicine</i>, 14th ed, Fauci AS, Braunwald E, Isselbacher KJ, et al, eds, New York, NY: McGraw-Hill, 1998, 1592.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15192356\"></a>Hurst S and McMillan M, &ldquo;Innovative Solutions in Critical Care Units: Extravasation Guidelines,&rdquo; <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy JH, &ldquo;Management of Systemic and Pulmonary Hypertension. <i>Tex Heart Inst J.</i> 2005;32(4):467-471.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/16429888/pubmed\" target=\"_blank\" id=\"16429888\">16429888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17509731\"></a>Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. <i>Ann Emerg Med</i>. 2007;50(2):144-152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/17509731/pubmed\" target=\"_blank\" id=\"17509731\">17509731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. <i>J Card Fail.</i> 2010;16(6):e1-e194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26370690\"></a>Mebazaa A, Tolppanen H, Mueller C, et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. <i>Intensive Care Med.</i> 2016;42(2):147-163. doi: 10.1007/s00134-015-4041-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/26370690/pubmed\" target=\"_blank\" id=\"26370690\">26370690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minitran (nitroglycerin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitro-Dur (nitroglycerin) [prescribing information]. Orlando, FL: Ingenus Pharmaceuticals LLC; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitro-Dur (nitroglycerin) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc: February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitro-Time (nitroglycerin) [prescribing information]. Farmingdale, NY: Time Cap Labs; October 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitrolingual (nitroglycerin) [prescribing information]. Jacksonville, FL: Espero Pharmaceuticals, Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitrolingual Pumpspray (nitroglycerin) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NitroMist (nitroglycerin) [prescribing information]. Cranford, NJ: Mist Pharmaceuticals, LLC; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitrostat (nitroglycerin) [prescribing information]. New York, NY: Parke-Davis; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitroglycerin in 5% Dextrose Injection (nitroglycerin) [prescribing information]. Deerfield, IL: Baxter; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Connor RE, Brady W, Brooks SC, et al, &quot;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Care Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):787-817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/20956226/pubmed\" target=\"_blank\" id=\"20956226\">20956226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    vO'Sullivan S and Keith MP, &quot;Raynaud phenomenon of the Nipple: A Rare Finding in Rheumatology Clinic,&quot; <i>J Clin Rheumatol</i>, 2011, 17(7):371-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/21946463/pubmed\" target=\"_blank\" id=\"21946463\">21946463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rangel-Castilla L, Gopinath S, Robertson CS. Management of intracranial hypertension. [published correction appears in <i>Neurol Clin</i>. 2008;26(3):xvii]. <i>Neurol Clin</i>. 2008;26(2):521-41, x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/18514825/pubmed\" target=\"_blank\" id=\"18514825\">18514825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24420913\"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stendra (avanafil) [prescribing information]. Chesterbrook, PA: Auxilium; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"401445\"></a>Swamy N, &ldquo;Esophageal Spasm: Clinical and Monometric Response to Nitroglycerin and Long Acting Nitrites,&rdquo; <i>Gastroenterology</i>, 1977, 72(1):23-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/401445/pubmed\" target=\"_blank\" id=\"401445\">401445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trujillo TC and Dobesh PP, &ldquo;Traditional Management of Chronic Stable Angina,&rdquo; <i>Pharmacotherapy</i>, 2007, 27(12):1677-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/18041888/pubmed\" target=\"_blank\" id=\"18041888\">18041888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westaby D, Hayes PC, Gimson AE, Polson RJ, Williams R. Controlled clinical trial of injection sclerotherapy for active variceal bleeding. <i>Hepatology</i>. 1989;9(2):274-277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/2492252/pubmed\" target=\"_blank\" id=\"2492252\">2492252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1447671\"></a>Wong AF, McCulloch LM, and Sola A, &ldquo;Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates,&rdquo; <i>J Pediatr</i>, 1992, 121(6):980-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/1447671/pubmed\" target=\"_blank\" id=\"1447671\">1447671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9706 Version 240.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202098\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F202099\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F202148\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F202103\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F20614012\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F202104\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20210506\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210507\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202076\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F202061\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50063776\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F803176\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472967\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472968\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F202079\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469146\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F202157\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4040394\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202082\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202065\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299768\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4039431\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202072\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11313090\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617179\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F202074\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202064\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F202081\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F202085\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F202086\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9706|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-patient-drug-information\" class=\"drug drug_patient\">Nitroglycerin (glyceryl trinitrate): Patient drug information</a></li><li><a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-pediatric-drug-information\" class=\"drug drug_pediatric\">Nitroglycerin (glyceryl trinitrate): Pediatric drug information</a></li></ul></div></div>","javascript":null}